odont Teraputics is developing a drug for breast cancer which is in stage 3 of the experiment after good results in stage 2.

Advantages of the drug compared to other treatments on the market:

- Instead of a combination of several chemical balls here it is only one ball.

- Instead of high doses of chemical drugs this pill is taken once in only 3 days!

- The chemicals from the pill stay in the human body for about 8 days which helps in lowering the dose of the drug.

No allergic reactions to the drug have been documented.

- Significantly positive results in the face of tumors that are resistant to chemotherapy.

The company plans to apply for drug registration with the FDA by mid-2021.

Some interesting data that strengthens the Long deal:

The company has a total of 39 million shares, of which approximately 19 million are tradable shares.

Institutional holding + face = 96% of the total shares of the company.

Shares in a short position = 3.6 million (note! - given as of 15.12), ie 19% of the tradable shares in a short position.

The average daily volume is about 380,000 shares - meaning closing full short positions will take about 10 days.

Cash burning rate = $ 10 million a month

Cash at checkout = $ 63 million

Which indicates accurate and correct planning in front of the FDA approval application deadline in exactly 6 months.

The financing is from the sale of shares and not from bank or non-bank loans, which makes it easier for the company to conduct itself at the economic level in the future.

Internal purchases of over one million shares worth more than $ 18 million in December alone!

At the technical level, a weekly graph, are in a bat pattern and we set off, crossing the average of 20 vessels up, the following resistance levels are marked on the graph.

Upside of about 100% and more.

money flow indicator indicates a large inflow of money inside.